Quantinno Capital Management LP Acquires 10,879 Shares of Stryker Co. (NYSE:SYK)

Quantinno Capital Management LP increased its position in shares of Stryker Co. (NYSE:SYK) by 47.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,706 shares of the medical technology company’s stock after acquiring an additional 10,879 shares during the quarter. Quantinno Capital Management LP’s holdings in Stryker were worth $12,177,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of SYK. Parnassus Investments LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $762,798,000. International Assets Investment Management LLC raised its stake in shares of Stryker by 66,967.5% during the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock worth $308,433,000 after acquiring an additional 852,496 shares in the last quarter. RTW Investments LP bought a new position in shares of Stryker during the 3rd quarter worth approximately $143,392,000. American Century Companies Inc. raised its stake in shares of Stryker by 287.6% during the 2nd quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company’s stock worth $172,033,000 after acquiring an additional 375,166 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in shares of Stryker by 49.8% during the 2nd quarter. Canada Pension Plan Investment Board now owns 686,416 shares of the medical technology company’s stock worth $233,553,000 after acquiring an additional 228,139 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now owns 10,042 shares in the company, valued at $3,685,213.16. The trade was a 42.25 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,781 shares of company stock valued at $24,612,275. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.3 %

NYSE:SYK opened at $389.76 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker Co. has a 1-year low of $285.79 and a 1-year high of $398.20. The firm has a market capitalization of $148.58 billion, a price-to-earnings ratio of 41.77, a price-to-earnings-growth ratio of 2.95 and a beta of 0.94. The stock has a fifty day simple moving average of $370.18 and a 200 day simple moving average of $352.79.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same period last year, the company posted $2.46 EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. Sell-side analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Truist Financial upped their price objective on shares of Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a report on Wednesday, October 30th. Robert W. Baird increased their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Barclays increased their price objective on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Canaccord Genuity Group raised their price objective on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Evercore ISI raised their price objective on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $398.40.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.